ArticleFrontiers in oncology2026
Age-related differences in clinical characteristics and survival in lung cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer predominantly affects older adults; however, an increasing number of cases are diagnosed in younger patients. Age-related differences in baseline characteristics, survival outcomes, and prognostic factors remain incompletely understood. This study aimed to compare clinical features, laboratory profiles, and survival outcomes between young and elderly patients with lung cancer and to identify prognostic factors associated with overall survival (OS) and progression-free survival (PFS). Methods: This retrospective cohort study screened patients with pathologically confirmed primary lung cancer diagnosed in 2022. Patients aged ≤45 years were classified as the young group, and those aged ≥75 years as the elderly group. Baseline demographic characteristics, laboratory parameters, and nutritional-inflammatory indices were compared between groups. Survival outcomes were evaluated using Kaplan-Meier analyses and compared with the log-rank test. Univariate and multivariate Cox proportional-hazards regression analyses were performed to identify prognostic factors for OS and PFS. Results: A total of 44 patients were included (21 young, 23 elderly). Elderly patients had higher smoking exposure and worse nutritional and inflammatory profiles, including lower albumin and prognostic nutritional index values. Younger patients showed significantly longer OS, while PFS was numerically longer but not statistically significant despite a tendency toward more advanced disease. In univariate analyses, histology type, gene mutation status, and treatment modality were associated with survival outcomes. In the simplified multivariable Cox models, immunotherapy was independently associated with improved OS, and targeted therapy, surgery, and immunotherapy were associated with better PFS. Conclusions: Young and elderly patients with lung cancer exhibit distinct clinical, laboratory, and survival profiles. Younger patients demonstrated more favorable genomic profiles and survival outcomes. These findings highlight the importance of age-specific evaluation and suggest that treatment-related and host-related factors should be considered in prognostic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.